[1] Egyptian National Control Strategy for Viral Hepatitis, 2008-2012.
[2] G. M. Lauer and B. D. Walke, “Hepatitis C Virus Infection,” The New England Journal of Medicine, Vol. 345, 2001, pp. 41-52. doi:10.1056/NEJM200107053450107
[3] K. W. Ray, “Global Epidemiology and Burden of Hepatitis C,” Microbes and Infection, Vol. 4, No. 12, 2002, pp. 1219-1225. doi:10.1016/S1286-4579(02)01649-0
[4] J. Stephanos, S. Hoel Jr., R. Timothy, D. Vijayan, et al., “Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose,” Annals of Internal Medicine, Vol. 140, No. 5, 2004, pp. 346-355. doi:10.7326/0003-4819-140-5-200403020-00010
[5] M. P. Manns, J. G. McHutchison, S. C. Gordon, V. K. Rustgi, et al., “Peginterferon Alfa-2b plus Ribavirin Compared with Interferon Alfa-2b plus Ribavirin for Initial Treatment of Chronic Hepatitis C: A Randomised Trial,” Lancet, Vol. 358, No. 9286, 2001, pp. 958-965. doi:10.1016/S0140-6736(01)06102-5
[6] S. S. Lee, E. J. Heathcote, K. R. Reddy, S. Zeuzem, et al., “Prognostic Factors and Early Predictability of Sustained Viral Response with Peginterferon Alfa-2a (40KD),” Journal of Hepatology, Vol. 37, No. 4, 2002, pp. 500-506. doi:10.1016/S0168-8278(02)00211-8
[7] G. L. Davis, J. B. Wong, J. G. McHutchison, M. P. Manns, et al., “Early Virologic Response to Treatment With Peginterferon Alfa-2b plus Ribavirin in Patients with Chronic Hepatitis C,” Hepatology, Vol. 38, No. 3, 2003, pp. 645-652. doi:10.1053/jhep.2003.50364
[8] N. Akuta, F. Suzuki, Y. Kawamura, H. Yatsuji, et al., “Predictive Factors of Early and Sustained Responses to Peginterferon plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus Genotype 1b: Amino Acid Substitutions in the Core Region and Low-Density Lipoprotein Cholesterol Levels,” Journal of Hepatology, Vol. 46, No. 3, 2007, pp. 403-410. doi:10.1016/j.jhep.2006.09.019
[9] M. W. Fried, M. L. Shiffman, K. R. Reddy, et al., “Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection,” The New England Journal of Medicine, Vol. 347, No. 13, 2002, pp. 975-982. doi:10.1056/NEJMoa020047
[10] K. L. Lindsay, C. Morishima, E. C. Wright, J. L. Dienstag, et al., “Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-Treatment of Chronic Hepatitis C,” Clinical Gastroenterology and Hepatology, Vol. 6, No. 2, 2008, pp. 234-241. doi:10.1016/j.cgh.2007.11.020
[11] C.-T. Wai, J. K. Greenson, R. J. Fontana, J. D. Kalbfleisch, et al., “A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C,” Hepatology, Vol. 38, No. 2, 2003, pp. 518-526. doi:10.1053/jhep.2003.50346
[12] M. Rodriguez-Torres, M. S. Sulkowski, R. T. Chung, F. M. Hamzeh and D. M. Jensen, “Factors Associated with Rapid and Early Virologic Response to Peginterferon Alfa-2a/Ribavirin Treatment in HCV Genotype 1 Patient’s Representative of the General Chronic Hepatitis C Population,” Journal of Viral Hepatitis, Vol. 17, No. 2, 2010, pp. 139-147. doi:10.1111/j.1365-2893.2009.01157.x
[13] M. Martinot-Peignoux, N. Boyer, M. Pouteau, C. Castelnau, et al., “Predictors of Sustained Response to Alpha Interferon Therapy in Chronic Hepatitis C,” Journal of Hepatology, Vol. 29, No. 2, 1998, pp. 214-223. doi:10.1016/S0168-8278(98)80006-8
[14] A. A. Abdo and F. M. Sanai, “Predictors of Sustained Virologic Response in Hepatitis C Genotype 4: Beyond the Usual Suspects,” Annals of Saudi Medicine, Vol. 29, 1, 2009, pp. 1-3. doi:10.4103/0256-4947.51810
[15] I. Namiki, A. Yasuhiro and K. Masayuki, “Predictors of Virological Response to a Combination Therapy with Pegylated Interferon plus Ribavirin Including Virus and Host Factors,” Hepatitis Research and Treatment, Vol. 2010, 2010, 7 Pages.
[16] S. Males, R. R. Gad, G. Esmat and H. Abobakr, “Serum Alpha-Foetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C,” Antiviral Therapy, Vol. 12, No. 5, 2007, pp. 797-803.
[17] M. F. Derbala, S. R. Al Kaabi, N. Z. El Dweik and F. Passic, “Treatment of Hepatitis C Virus Genotype 4 with Peginterferon Alfa-2a: Impact of Bilharziasis and Fibrosis Stage,” World Journal of Gastroenterology, Vol. 12, No. 35, 2006, pp. 5692-5698.
[18] A. Ascione, M. De Luca, M. T. Tartaglione, F. Lampasi, et al., “Peginterferon Alfa-2a plus Ribavirin Is More Effective than Peginterferon Alfa-2b plus Ribavirin for Treating Chronic Hepatitis C Virus Infection,” Gastroenterology, Vol. 138, No. 1, 2010, pp. 116-122. doi:10.1053/j.gastro.2009.10.005
[19] B. O. De Careaga, “Predictive Factors for Response to Treatment of Chronic Hepatitis C,” Annals of Hepatology, Vol. 5, Suppl. 1, 2006, pp. s24-s28.
[20] J. A. Mata-Marín, J. L. Fuentes-Allen, J. Gaytán-Martínez, B. Manjarrez-Téllez, et al., “APRI as a Predictor of Early Viral Response in Chronic Hepatitis C Patients,” World Journal of Gastroenterology, Vol. 15, No. 3, 2009, pp. 4923-4927. doi:10.3748/wjg.15.4923